Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield Iowa Zycubo Coverage | Open…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.06.30

    Zycubo (copper histidinate) Coverage

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.06.30 alerts

    Get alerted when Policy 05.06.30 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Zycubo in pediatric and continuing-treatment patients with Menkes disease. Coverage depends on diagnosis, age or prior treatment status, clinical response, documentation, prescriber qualifications, and applicable quantity limits.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyZycubo (copper histidinate) Coverage
    Policy CodePolicy 05.06.30
    Change TypeNo material change
    Effective DateOct 3, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation confirming Menkes disease and ensure the medication is prescribed by or in consultation with a qualified specialist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Menkes diseaseCovered indication
    ≤17 yearsInitial age limit
    6 monthsInitial authorization
    12 monthsContinuation authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    60 vials/30 days
    Quantity limit
    OHSExcluded condition

    Coverage Criteria

    Occipital Horn Syndrome (OHS) is not an indicated use of Zycubo and is excluded from coverage. Coverage will not be provided for members diagnosed with OHS.

    Zycubo (copper histidinate) is considered not medically necessary when the member does not meet the coverage criteria set forth in this policy.

    Initial Therapy

    Covered for initial therapy when all of the following are met:

    Initial Menkes disease approval

    • Age requirement: Member is ≤17 years of age.
    • Diagnostic pathway

      • Biochemical or genetic confirmation: Biochemical testing shows plasma catecholamine abnormalities, including elevated DOPAC:DHPG and dopamine:norepinephrine ratios, or genetic testing confirms an ATP7A mutation consistent with a severe Menkes disease phenotype.Elevated DOPAC:DHPG and dopamine:norepinephrine ratios or qualifying ATP7A mutation

        Confirmation is required on continuation approval.

      • Clinical diagnosis while testing is pending: Clinical signs and symptoms, including characteristic Menkes kinky hair, skin abnormalities, progressive neurologic impairment, growth and developmental delays, and multisystem complications affecting the brain, bones, and connective tissues, are strongly consistent with Menkes disease, and treatment delay would result in harm.

    Continuation Therapy

    Covered for continuation therapy when all of the following are met:

    Continuation Menkes disease approval

    • Prior treatment: Member previously received treatment with Zycubo or compounded copper histidinate before FDA approval.
    • Response and tolerability: Member is experiencing a positive clinical response and has no evidence of unacceptable toxicity.
    • Confirmed diagnosis when required: If the diagnosis was not confirmed during initial approval, genetic or biochemical testing confirms Menkes disease.
    • Benefit-risk assessment beyond 3 years: Continued benefit-to-risk for treatment beyond a total treatment duration of 3 years is documented.

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Required

    Prior authorization is required. A 6-month authorization may be granted for treatment of Menkes disease in eligible members age 17 or younger when the coverage criteria are met.

    • Member is ≤ 17 years of age.
    • Authorization period: 6 months.
    Prior Authorization

    Qualified Prescriber Required

    The requested medication must be prescribed by or in consultation with a qualified specialist.

    • Neurologist
    • Geneticist
    • Specialist in the treatment of Menkes disease

    Clinical Background

    Zycubo (copper histidinate) is covered for the treatment of Menkes disease in pediatric patients. Menkes disease is associated with characteristic kinky hair, skin abnormalities, progressive neurologic impairment, growth and developmental delays, and multisystem complications involving the brain, bones, and connective tissues.

    Policy Definitions

    Biochemical or Genetic Confirmation
    Biochemical confirmationPlasma catecholamine analysis showing elevated DOPAC:DHPG and dopamine:norepinephrine ratios.
    Genetic confirmationATP7A mutation consistent with a severe Menkes disease phenotype.
    Continuation requirementBiochemical or genetic testing must be confirmed on continuation approval.
    Occipital Horn Syndrome (OHS)
    ConditionOccipital Horn Syndrome (OHS).
    IndicationZycubo is not indicated for the treatment of OHS.
    Coverage status

    Menkes Disease Initial Approval

    Menkes Disease Initial Approval

    Initial approval may be granted for 6 months when all of the following criteria are met:

    Menkes disease initial therapy: Member is 17 years of age or younger and has Menkes disease confirmed biochemically or genetically, or has strongly consistent clinical signs and symptoms while testing is pending when treatment delay would result in harm.≤17 years; 6-month authorization

    Biochemical or genetic testing must be confirmed on continuation approval when applicable.

    Menkes Disease Continuation

    Menkes Disease Continuation

    Continuation approval may be granted for 12 months when all of the following criteria are met:

    Menkes disease continuation: Member previously received Zycubo or compounded copper histidinate before FDA approval; is experiencing positive clinical response without unacceptable toxicity; has genetic or biochemical confirmation of Menkes disease if not previously confirmed; and has documented continued benefit-to-risk for treatment beyond 3 years total treatment duration.12-month authorization; beyond 3 years requires continued benefit-to-risk documentation

    Applies to all members, including new members.

    Dose and Quantity Limits

    Standard Quantity Limit
    MedicationZycubo (copper histidinate) 2.9 mg/0.5 mL vial.
    Standard quantity limit60 vials per 30 days.
    Single-use handlingThe unused portion must be discarded after each single use.
    FDA-Recommended Dosing
    Patients younger than 1 year1.45 mg subcutaneously twice daily.
    Patients 1 to 17 years of age1.45 mg administered subcutaneously once daily.
    Dosage formZycubo (copper histidinate) 2.9 mg/0.5 mL vial.
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyZycubo (copper histidinate) Coverage
    Policy CodePolicy 05.06.30
    Change TypeNo material change
    Effective DateOct 3, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation confirming Menkes disease and ensure the medication is prescribed by or in consultation with a qualified specialist.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Documentation RequirementsClinical BackgroundPolicy DefinitionsMenkes Disease Initial ApprovalMenkes Disease ContinuationDose and Quantity Limits
    >3 years total treatment duration
    Prior Authorization

    Continuation Authorization

    A 12-month authorization may be granted for continued treatment in all members, including new members, when continuation criteria are met.

    • Member previously received Zycubo or compounded copper histidinate before FDA approval.
    • Member is experiencing a positive clinical response with no unacceptable toxicity.
    • If the diagnosis was not confirmed at initial approval, genetic or biochemical testing confirms Menkes disease.
    • Documentation supports continued benefit-to-risk for treatment beyond 3 years total duration.
    Documentation Required

    Initial Diagnostic Documentation

    For an initial request, submit chart notes or medical records confirming Menkes disease through laboratory or genetic testing, or through compatible clinical signs and symptoms.

    • Biochemical evidence may include plasma catecholamine analysis with elevated DOPAC:DHPG and dopamine:norepinephrine ratios.
    • Genetic evidence may include confirmation of an ATP7A mutation consistent with a severe Menkes disease phenotype.
    • Clinical evidence may include characteristic Menkes kinky hair, skin abnormalities, progressive neurologic impairment, growth and developmental delays, or multisystem complications affecting the brain, bones, and connective tissues.
    Documentation Required

    Continuation Documentation

    For a continuation request, submit chart notes or medical records confirming Menkes disease and documenting ongoing clinical benefit from treatment.

    • Confirm diagnosis by laboratory or genetic testing, if applicable.
    • Document a positive clinical response from baseline.
    Documentation Required

    Pending Diagnostic Results

    When biochemical or genetic results are pending, coverage may be considered only when the clinical presentation is strongly consistent with Menkes disease and delaying treatment would result in harm.

    • Document strongly consistent clinical signs and symptoms.
    • Document that biochemical or genetic results are pending.
    • Document that treatment delay would result in harm.

    Unsupported block type: denial_riskแcallout

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk مش

    Coverage will not be provided for members diagnosed with OHS.